Zoledron 5 mg/100 ml (IV Infusion)
100 ml bottle: ৳ 5,950.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Zoledronic acid for osteoporosis |
| Company | Opsonin pharma ltd |
Indications
- Treatment and prevention of postmenopausal osteoporosis
- Treatment to increase bone mass in men with osteoporosis
- Treatment and prevention of glucocorticoid-induced osteoporosis
- Treatment of Paget’s disease of bone in men and women
Pharmacology
- Bisphosphonate
- Inhibitor of osteoclast-mediated bone resorption
- High affinity for mineralized bone
- Rapid partitioning to bone
- Localizes preferentially at sites of high bone turnover
- Molecular target in the osteoclast: farnesyl pyrophosphate synthase
- Long duration of action due to high binding affinity to bone mineral
Dosage
- 5 mg infusion once a year for postmenopausal osteoporosis in women
- 5 mg infusion once every 2 years for prevention of osteoporosis in postmenopausal women
- 5 mg infusion once a year for osteoporosis in men
- 5 mg infusion once a year for glucocorticoid-induced osteoporosis
- 5 mg infusion for treatment of Paget’s disease of bone
- Calcium and vitamin D supplementation for Paget’s disease and osteoporosis patients
Administration
- Intravenous infusion over no less than 15 minutes
- Appropriate hydration prior to administration
- Visual inspection for particulate matter and discoloration
- Normal saline flush after infusion
- Avoid contact with calcium-containing solutions
- Stability of solution after opening
Interaction
- Aminoglycosides may lower serum calcium
- Loop diuretics may increase risk of hypocalcemia
- Nephrotoxic drugs use with caution
- Drugs excreted by the kidney exposure may be increased with renal impairment
Contraindications
- Hypocalcemia
- Creatinine clearance less than 35 mL/min
- Acute renal impairment
- Hypersensitivity to any component of Zoledronic Acid
Side Effects
- Pyrexia
- Myalgia
- Headache
- Arthralgia
- Pain in extremity
- Flu-like illness
- Nausea
- Vomiting
- Diarrhea
- Eye inflammation
Pregnancy & Lactation
- Fetal harm potential
- Not for nursing women
Precautions & Warnings
- Hypocalcemia supplementation
- Renal impairment caution
- Osteonecrosis of the Jaw (ONJ) risk
- Atypical Femur Fractures
- Severe Bone, Joint, and Muscle Pain
Use in Special Populations
- Not indicated for use in pediatric patients
- Special care for geriatric use
- Renal impairment contraindication
- No clinical data for hepatic impairment use
Overdose Effects
- Clinically significant renal impairment
- Hypocalcemia
- Hypophosphatemia
- Hypomagnesemia
- Correction of serum levels with intravenous administration of specific substances
- Dosage and infusion duration limits
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Store below 30°C
- Protect from moisture and light
- Keep out of reach and sight of children